1. Home
  2. MRKR vs NNVC Comparison

MRKR vs NNVC Comparison

Compare MRKR & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • NNVC
  • Stock Information
  • Founded
  • MRKR N/A
  • NNVC 2005
  • Country
  • MRKR United States
  • NNVC United States
  • Employees
  • MRKR N/A
  • NNVC N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • NNVC Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRKR Health Care
  • NNVC Health Care
  • Exchange
  • MRKR Nasdaq
  • NNVC Nasdaq
  • Market Cap
  • MRKR 16.1M
  • NNVC 23.5M
  • IPO Year
  • MRKR N/A
  • NNVC N/A
  • Fundamental
  • Price
  • MRKR $1.18
  • NNVC $1.21
  • Analyst Decision
  • MRKR Strong Buy
  • NNVC Strong Buy
  • Analyst Count
  • MRKR 2
  • NNVC 1
  • Target Price
  • MRKR $13.50
  • NNVC $6.50
  • AVG Volume (30 Days)
  • MRKR 239.7K
  • NNVC 238.5K
  • Earning Date
  • MRKR 03-25-2025
  • NNVC 02-14-2025
  • Dividend Yield
  • MRKR N/A
  • NNVC N/A
  • EPS Growth
  • MRKR N/A
  • NNVC N/A
  • EPS
  • MRKR N/A
  • NNVC N/A
  • Revenue
  • MRKR $5,395,849.00
  • NNVC N/A
  • Revenue This Year
  • MRKR $195.40
  • NNVC N/A
  • Revenue Next Year
  • MRKR N/A
  • NNVC N/A
  • P/E Ratio
  • MRKR N/A
  • NNVC N/A
  • Revenue Growth
  • MRKR 79.04
  • NNVC N/A
  • 52 Week Low
  • MRKR $1.13
  • NNVC $1.03
  • 52 Week High
  • MRKR $5.99
  • NNVC $3.59
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 33.38
  • NNVC 46.05
  • Support Level
  • MRKR $1.35
  • NNVC $1.11
  • Resistance Level
  • MRKR $1.99
  • NNVC $1.31
  • Average True Range (ATR)
  • MRKR 0.22
  • NNVC 0.12
  • MACD
  • MRKR 0.01
  • NNVC -0.01
  • Stochastic Oscillator
  • MRKR 5.21
  • NNVC 22.73

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Share on Social Networks: